This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vertex Advances One of Two Hep C Drugs

Stocks in this article: VRTX GILD BMY IDIX

CAMBRIDGE, Mass. ( TheStreet) -- Vertex Pharmaceuticals (VRTX) is advancing one experimental hepatitis C drug into mid-stage clinical trials while shutting down work on a second drug due to poor efficacy, the company announced Tuesday.

Both Vertex drugs, ALS-2200 and ALS-2158 belong to the class of hepatitis C drugs known as nucleotide (or nucleoside) polymerase inhibitors -- commonly referred to as "nucs" -- which have the potential to become the backbone of new, all-oral combination regimens.

The current superstar of the "nuc" drug class is Gilead Sciences' (GILD) GS-7977, but Bristol-Myers Squibb (BMY) was forced to abandon its nuc BMS-094 because it caused heart failure. The fallout from Bristol's drug has since spread to Idenix Pharmaceuticals (IDIX) and its nuc IDX-184, which is on clinical hold until U.S. regulators are assured the drug is safe.

The combination of ALS-2200 plus ribavirin yielded a 4.2 log10 reduction in viral load after seven days of dosing in previously untreated, genotype 1 hepatitis C patients. Eight patients were treated, of which five were able to achieve undetectable levels of the hepatitis C virus, Vertex announced Tuesday.

Vertex also disclosed that the "uridine" chemical structure of ALS-2200 is the same as Gilead's GS-7977. This is important since the recent safety issues related to nucs appear to be limited to those drugs with a "purine" chemical structure.

Based on these results, Vertex plans to move ALS-2200 into two, phase II studies. One study will evaluate ALS-2200 in combination with ribavirin, the other study will combine ALS-2200 with Vertex's currently marketed hepatitis C drug Incivek. Vertex is discussing the new studies with regulatory agencies and hopes to begin enrollment before the end of the year.

While Vertex is making progress towards developing an all-oral regimen for hepatitis C, the work being done by Gilead and others is still considerably in the lead. Vertex's ALS-2200 may also be less potent than GS-7977.

Vertex's ALS-2158 will not be moving ahead into new studies due to insufficient antiviral activity, the company said.

Vertex shares were down 1.5% to $57.86 in early Tuesday trading.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs